While the dollar amount is modest relative to market cap (<0.1%), the concentration of sales among top executives—including the CEO and CFO—shortly after large option exercises suggests profit-taking and raises caution. Monitor for any follow-up filings or news that could indicate broader sentiment shifts.
Price Chart
Executive Summary
Four corporate insiders at United Therapeutics, including the CEO, CFO, and General Counsel, conducted open-market share sales totaling $1.29 million over a 7-day window, following derivative exercises. The net direction is clearly selling, with the largest individual sale by a director accounting for nearly half the total value.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $89,732 in open-market transactions and exercised derivatives worth over $3.8 million in non-cash transactions.
- CFO James Edgemond sold $503,649 in shares after exercising options valued at $2.7 million.
- Director Christopher Patusky sold $578,880 of shares, the largest single transaction in the cluster.
- General Counsel Paul Mahon sold $114,807 in shares following derivative exercises worth $1.2 million.
- Total open-market sell value: $1.29 million (0.005% of $25.1B market cap), all within a 7-day period.
Financial Impact
$1.29 million in open-market share sales by insiders
Risk Factors
- Perception of insider confidence erosion, especially given CEO and CFO participation.
- Potential for negative market reaction if seen as coordinated profit-taking post-exercise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1776889897225 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $571.38 (+14.20%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $571.38 (+14.94%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $571.38 (+13.40%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $571.38 (+12.74%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $571.38 (+17.18%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $571.38 (+17.05%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $571.38 (+10.85%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $571.38 (+8.23%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $571.38 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access